Carcinoid Of Rectum Research Articles

Treatment of Metastatic Carcinoid Tumors and the Carcinoid Syndrome with Recombinant interferon Alpha

Fourteen patients with metastatic carcinoid tumors were treated with recombinant interferon alpha-2b at a dosage of 3-4 x 10(6) IU s.c. daily or every second day. No objective tumor regression was observed. Six out of 8 patients with carcinoids of the ileum and the caecum showed stable disease lasting for a median of 25 months (range 4-57). In 3 out of 6 patients with carcinoids of rectum, lung and of unknown primary site, stable disease was observed lasting for 2-7 months. The remaining patients had progressive disease. Six out of 9 evaluable patients had a more than 50% reduction of urinary 24 h 5-hydroxyindoleacetic acid excretion lasting for a median of 4 months (range 2-11). Decrease of flushing was noticed in 3 out of 6 evaluable patients and decrease of diarrhea in 5 out of 9 evaluable patients. In 4 patients dose reduction was necessary due to confusion and fatigue.

Carcinoid of the rectum: A report of three cases

1. 1. Three cases of carcinoid of rectum are reported. 2. 2. All small lesions of rectum should be completely removed and entire specimen considered biopsy material. 3. 3. Periodic examinations of patients from whom carcinoid tumors have been removed are indicated and should include barium enema with air contrast. 4. 4. All tissue removed from anus and rectum should be subjected to pathologic examination to insure proper diagnosis and subsequent treatment. 5. 5. Carcinoid of the rectum must be considered in any pathologic report of a rectal lesion showing intact mucous membrane with underlying tumor tissue suggesting carcinoma of rectum. A correct evaluation of the lesion may avoid unnecessary resection of the rectum.